NLS New Market

BONESUPPORT announces that it has signed an Agency agreement with Novomedics to provide it with local support to initiate access to French market. Novomedics, which is based in Metz, has significant experience in the bone substitute field. BONESUPPORT’s CERAMENT product line of CERAMENT BONE VOID FILLER (BVF), CERAMENT G and CERAMENT V will be commercialized […]

Medivir and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China. Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered […]

Xbrane Biopharma’s partner Pooyesh Darou has been granted market authorization for sales and marketing of Spherotide 1 month formulation in Iran under the local brand name Microrelin. “This is a major milestone for Xbrane as it is the first Market Authorization granted for Spherotide to a local sales and marketing partner. This demonstrates the quality […]

Oasmia Pharmaceutical has received marketing approval of Doxophos in Russia. The company marks this as a key milestone following the recently established relationship with Hetero Group, its new marketing and distribution partner. Doxophos has been approved for use in the treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, […]

LEO Pharma has announced that the European Commission has granted marketing authorization for Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum is the first and only biologic that selectively targets the IL-17 receptor subunit A. It is different from existing therapies. […]

The US Food and Drug Administration has approved the Scibase Pre-Market Approval (PMA) for its product Nevisense. Nevisense is SciBase’s device for the early detection of malignant melanoma. With the approval, SciBase can now market and sell Nevisense in the US.  According to the letter from the FDA the device is: ‘intended for use on […]